证券代码：000403 证券简称：派林生物 公告编号：2025-038 派斯双林生物制药股份有限公司 关于2025年度续聘审计机构的公告 本公司及董事会全体成员保证信息披露的内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 重要内容提示： 1、拟续聘的审计机构名称：毕马威华振会计师事务所（特殊普通合伙）（以下简 称"毕马威华振"）。 2、本次续聘会计师事务所符合财政部、国资委及证监会联合下发的《国有企业、 上市公司选聘会计师事务所管理办法》的相关规定。 公司于 2025 年 8 月 20 日召开第十届董事会第十七次会议（临时会议）审议通过了 《关于公司 2025 年度续聘审计机构的议案》，拟续聘毕马威华振为公司 2025 年度财务 报告及内部控制审计机构，并提请公司 2025 年第二次临时股东大会审议，具体内容公 告如下： 一、拟续聘审计机构的基本情况 （一）机构信息 1、基本信息 毕马威华振会计师事务所于 1992 年 8 月 18 日在北京成立，于 2012 年 7 月 5 日获 财政部批准转制为特殊普通合伙的合伙制企业，更名为毕马威华振，2012 年 7 月 10 日 取得工商营业执照， ...

派斯双林生物制药股份有限公司 2025 年半年度财务报告 派斯双林生物制药股份有限公司 2025 年半年度财务报告 2025 年 8 月 22 日 1 派斯双林生物制药股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的单位为：元 1、合并资产负债表 单位：元 | 项目 | 期末余额 | 期初余额 | | --- | --- | --- | | 流动资产： | | | | 货币资金 | 559,086,605.74 | 1,321,124,262.61 | | 结算备付金 | | | | 拆出资金 | | | | 交易性金融资产 | 477,097,058.24 | 282,702,336.48 | | 衍生金融资产 | | | | 应收票据 | 53,598,738.36 | 37,768,154.86 | | 应收账款 | 576,516,718.01 | 631,221,831.05 | | 应收款项融资 | 18,784,578.91 | 41,696,512.81 | | 预付款项 | 26,158,2 ...

证券代码：000403 证券简称：派林生物 公告编号：2025-041 派斯双林生物制药股份有限公司 关于海外市场法规注册出口贸易重大合同进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 派斯双林生物制药股份有限公司（以下简称"公司"）全资子公司广东双林生物 制药有限公司（以下简称"广东双林"）于近日与BRAINFARMA INDÚSTRIA QUÍMICA E FARMACÊUTICA S.A.（以下简称"BRAINFARMA"）签订了《共同终 止协议》，具体情况公告如下： 注人免疫球蛋白（10%）及其他产品海外法规注册出口工作，并做好重大项目执行 的风险防控，推动公司海外出口业务的长远稳健发展。 特此公告。 派斯双林生物制药股份有限公司 公司于2022年4月16日发布了《关于公司海外市场法规注册出口贸易签订双向排 他合作框架协议的公告》（公告编号：2022-028），公司为大力推动海外出口销售工 作，寻求海外市场法规注册出口的长期贸易机会，公司全资子公司广东双林与 BRAINFARMA签订了《双向排他合作框架协议》，后广东双林与BRAINFAR ...

主管会计工作负责人: 会计机构负责人: 第1页 2025年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位: 万元 编制单位:派斯双 2025年半年度期末占 2025年半年度偿还紧 上市公司核算 | 2025年期初占用资金 | 2025年半年度占用累计发 | 2025年半年度占用资金的利 占用形成原因 占用性质 占用方与上市公司 非经营性 用资金余额 上国方义 计发生金额 息(如有) 生金额(不含利息) 余额 的关联关系 的会计科目 资金占用 控股股东、 际控制人及其 附属企业 0530298 小计- 前控股股东、 实际控制人及 其附属企业 小计 其他关联方及 其附属企业 小计 总计 往来性质(经 2025年半年度期末往 2025年半年度往来资金的利 2025年半年度偿还紧 上市公司核算 | 2025年期初往来资金 | 2025年半年度往来累计发 哲性往来、非 往来方与上市公司 往来形成原因 其他关联 资金往来方名称 来资金余额 计发生金额 息(如有) 生金额(不含利息) 经营性往来) 余额 的关联关系 的会计科目 资金往来 同一实际控制人控制 4.40 采购服务 经营性往米 4.40 预付账款 控股 ...

证券代码：000403 证券简称：派林生物 公告编号：2025-039 派斯双林生物制药股份有限公司 关于召开2025年第二次临时股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、召开会议基本情况 7、出席对象： （1）于股权登记日下午收市时，在中国证券登记结算有限责任公司深圳分公司 登记在册的本公司全体普通股股东均有权出席本次股东大会，并可以书面委托代理 1、股东大会届次：2025 年第二次临时股东大会 2、股东大会召集人：公司董事会，本次股东大会经公司第十届董事会第十七次 会议（临时会议）决议召开。 3、会议召开的合法、合规性：本次会议的召集和召开符合《中华人民共和国公 司法》《派斯双林生物制药股份有限公司章程》的有关规定，合法有效。 4、会议召开时间： 现场会议时间：2025 年 9 月 8 日（星期一）15:00 网络投票时间：其中，通过深圳证券交易所交易系统网络投票的时间为：2025 年 9 月 8 日上午 9:15—9:25；9:30—11:30，下午 13:00—15:00；通过深圳证券交易所 互联网投票系统网络投票时间为：20 ...

证券代码：000403 证券简称：派林生物 公告编号：2025-036 派斯双林生物制药股份有限公司 第十届监事会第十一次会议（临时会议）决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 派斯双林生物制药股份有限公司（以下简称"公司"）第十届监事会第十一次会 议（临时会议）于2025年8月20日以通讯方式召开，会议由公司监事会主席郭麾先生 召集并主持。本次会议通知于2025年8月17日以通讯方式发出，会议应出席监事5人， 实际出席监事5人，会议程序符合《中华人民共和国公司法》和《派斯双林生物制药 股份有限公司章程》的有关规定。 与会监事经过认真讨论，审议了以下议案： 1、《2025 年半年度报告》 经审核，监事会认为董事会编制和审议公司 2025 年半年度报告的程序符合法律、 行政法规及中国证监会的规定，报告内容真实、准确、完整地反映了上市公司的实 际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。具体内容详见《派斯双 林生物制药股份有限公司 2025 年半年度报告全文》《派斯双林生物制药股份有限公 司 2025 年半年度报 ...

证券代码：000403 证券简称：派林生物 公告编号：2025-035 派斯双林生物制药股份有限公司 第十届董事会第十七次会议（临时会议）决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 派斯双林生物制药股份有限公司（以下简称"公司"）第十届董事会第十七次会 议（临时会议）于2025年8月20日以通讯方式召开，会议由公司董事长李昊先生召集 并主持。本次会议通知于2025年8月17日以通讯方式发出，会议应出席董事13人，实 际出席董事13人，会议程序符合《公司法》和《公司章程》的有关规定。 二、董事会会议审议情况 与会董事经过认真讨论，审议了以下议案： 1、《2025 年半年度报告》 公司 2025 年半年度报告全文及摘要按照中国证监会印发的《公开发行证券的公 司信息披露内容与格式准则第 3 号——半年度报告的内容与格式》及深圳证券交易 所发布的《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运 作》的要求编制。具体内容详见《派斯双林生物制药股份有限公司 2025 年半年度报 告全文》《派斯双林生物制药股份有限 ...

Core Insights - The company reported a revenue of 986 million yuan for the first half of 2025, representing a year-on-year decline of 13.18% [2] - The net profit for the same period was 236 million yuan, down 27.89% year-on-year [2] - The company announced plans not to distribute cash dividends, issue bonus shares, or increase capital through reserves [2] Financial Performance - Revenue: 986 million yuan, down 13.18% year-on-year [2] - Net Profit: 236 million yuan, down 27.89% year-on-year [2] Dividend Policy - No cash dividends will be distributed [2] - No bonus shares will be issued [2] - No capital increase through reserves will occur [2]

Financial Performance - The company's operating revenue for the first half of 2025 was ¥986,481,770.22, a decrease of 13.18% compared to ¥1,136,178,207.09 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was ¥235,792,903.00, down 27.89% from ¥326,984,394.22 year-on-year[19]. - The net profit after deducting non-recurring gains and losses was ¥214,668,744.31, reflecting a decrease of 27.63% compared to ¥296,625,321.89 in the previous year[19]. - The net cash flow from operating activities was -¥192,663,897.79, a significant decline of 270.71% from ¥112,858,305.14 in the same period last year[19]. - Basic earnings per share decreased by 26.47% to ¥0.25 from ¥0.34 year-on-year[19]. - Total assets at the end of the reporting period were ¥9,081,296,122.69, down 1.78% from ¥9,246,269,365.26 at the end of the previous year[19]. - The net assets attributable to shareholders of the listed company were ¥7,904,564,897.89, a slight decrease of 0.25% from ¥7,924,650,751.55 at the end of the previous year[19]. - The weighted average return on net assets was 2.93%, a decrease of 1.46 percentage points compared to 4.39% in the previous year[19]. Market Outlook - The global blood products market is expected to exceed $50 billion in 2024 and $90 billion by 2030[27]. - China's blood products market is projected to reach ¥60 billion in 2024 and ¥95 billion by 2030, indicating significant growth potential[28]. - The blood products industry in China has a high entry barrier, with fewer than 30 operational companies due to strict regulatory controls[29]. - The supply of raw plasma in China is relatively insufficient, with over 60% of human albumin relying on imports[32]. - The blood products industry in China is expected to experience continuous high growth due to factors such as economic development and an aging population[35]. - The industry is undergoing consolidation, with leading companies gaining more market share, reflecting a trend towards oligopoly[35]. Company Strategy and Operations - The company aims to achieve a plasma collection volume exceeding 1,400 tons in 2024, positioning itself among the top tier in the blood products industry[36]. - The company has expanded its product offerings to 11 types and increased its plasma station count to 38 through strategic partnerships and acquisitions[36]. - The company has established strategic cooperation with Xinjiang Deyuan to enhance plasma sourcing and increase station numbers[36]. - The company emphasizes quality management, having achieved ISO9001 certification and other quality management accolades, ensuring product safety and effectiveness[45]. - The company’s strategic focus includes both organic growth and external expansion to meet increasing operational demands[43]. Financial Management and Investments - The company raised a total of ¥1,599,999,984.00 through a private placement of 48,004,800 shares at a price of ¥33.33 per share, with a net amount of ¥1,575,241,979.20 after deducting issuance costs[71]. - The company has established a special account for the management of raised funds, ensuring that all funds are stored in a designated account[72]. - The company has committed to use raised funds for specific projects, with ongoing monitoring of investment progress[74]. - The company plans to increase the investment in the new blood plasma station construction project from CNY 250 million to CNY 405 million due to changes in project planning and external environment[75]. - The total investment for the new product research and supporting production line construction project is CNY 355.5 million, with CNY 340.5 million allocated from raised funds[76]. Risk Management - The company has detailed the risks it may face in the management discussion and analysis section of the report[4]. - The company faces risks related to national regulatory policies, raw material supply shortages, market competition, and product development, which could impact its operations[85][86][87][88]. - The company has implemented measures to enhance internal control systems and comply with regulatory requirements to mitigate identified risks[89]. - The regulatory environment is becoming stricter, which may impact short-term operations but will benefit long-term industry health and consolidation[30]. Shareholder and Governance - The company ensures the independence of its operations, assets, and financial management from its controlling entities, with commitments fulfilled as of March 28, 2023[109]. - The company has committed to maintaining independent personnel management, with senior management not holding positions in controlling entities beyond board roles[109]. - The company has pledged to avoid any form of competition with its controlling entities, ensuring no overlap in core business activities[109]. - The company has committed to a transparent process for recommending board members and executives, ensuring no undue influence from controlling entities[109]. Compliance and Regulatory Issues - The semi-annual financial report has not been audited[114]. - The company received a regulatory decision from the Shanxi Securities Regulatory Bureau on May 12, 2025, requiring corrective actions due to internal control deficiencies and inaccurate information disclosure[118]. - The company held a board meeting on May 30, 2025, to approve a comprehensive rectification plan addressing the issues raised in the regulatory decision[119]. - The company is committed to continuous improvement in compliance and internal controls following the regulatory findings[119].

Group 1 - The company announced the approval of two key resolutions during the 2025 first extraordinary general meeting of shareholders, including the change of the legal representative and the decision to abandon the acquisition opportunity of Palin Bio [2] - The decision to change the legal representative indicates a potential shift in management strategy or corporate governance [2] - The abandonment of the acquisition opportunity suggests a strategic refocus or reassessment of growth opportunities within the industry [2]